Poor 1st-year Adherence to Anti-osteoporotic Therapy Increases the Risk of Mortality in Patients with Magnetic Resonance Imaging-proven Acute Osteoporotic Vertebral Fractures

Overview

Journal Patient Prefer Adherence

Date 2017 May 12

PMID 28490865

Citations 10

Authors

Ying-Chou Chen

Wei-Che Lin

Affiliations

Soon will be listed here.

Abstract

Aim: Anti-osteoporotic therapy requires years of proper compliance to reduce the risk of fractures. This study investigated the effects of 1st-year adherence to anti-osteoporotic treatment on the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures after vertebroplasty.

Patients And Methods: This retrospective study included 294 patients (252 females; mean age, 73.93±7.18 years) with osteoporosis and acute vertebral fractures treated with vertebroplasty between January 2001 and December 2007. Sex, age, body mass index, comorbidities, previous hip fracture, number of vertebral fractures, 5-year re-fracture rate, and use of anti-osteoporotic therapy were recorded for each patient. Adherence was determined according to compliance and persistence for 1 year. Compliance was calculated as the medication possession ratio (MPR), and persistence as the time from treatment initiation to discontinuation. Poor adherence was defined as either non-compliance or non-persistence.

Results: The MPR of the patients at 1 year was 55.1%, with a persistence rate of 69.4% and a poor adherence rate of 62.6%. Cox regression analysis revealed that poor adherence to medications was associated with a significantly higher risk of mortality after adjustment for potential confounders (hazard ratio [HR]: 1.75; 95% CI: 1.13-2.71). Poor adherence to medications was significantly associated with an increase in the rate of infection (HR: 4.56; 95% CI: 1.12-18.52), which was the most common cause of death.

Conclusion: Poor adherence to anti-osteoporotic therapy significantly increases the risk of morality, possibly due to an increased risk of infection. Efforts should be made to improve adherence.

Citing Articles

Effects of Frailty Syndrome on Osteoporosis, Focusing on the Mediating Effect of Muscle Strength and Balance in Community-Dwelling Older Adults (≥60 years) in Iran: Results From the Amirkola Health and Aging Project Cohort Study.

Shamsalinia A, Hosseini S, Bijani A, Ghadimi R, Kordbageri M, Saadati K Geriatr Orthop Surg Rehabil. 2024; 15:21514593241264647.

PMID: 39070931 PMC: 11273585. DOI: 10.1177/21514593241264647.

Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on 'Diagnosis, risk stratification, and continuity of care of fragility fractures' based on a systematic literature review.

Migliaccio S, Moretti A, Biffi A, Ronco R, Porcu G, Adami G Ther Adv Musculoskelet Dis. 2023; 15:1759720X231177110.

PMID: 37359175 PMC: 10286165. DOI: 10.1177/1759720X231177110.

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R Front Endocrinol (Lausanne). 2023; 14:1137671.

PMID: 37143730 PMC: 10151776. DOI: 10.3389/fendo.2023.1137671.

Mediating Medical Comorbidities in Geriatric Patients Undergoing Surgery for OVCF: From Preoperative Screening to Risk and Outcomes Optimization.

Scheyerer M, Lenz M, Jacobs C, Pumberger M, Spiegl U, Ullrich B Global Spine J. 2023; 13(1_suppl):6S-12S.

PMID: 37084354 PMC: 10177309. DOI: 10.1177/21925682221130050.

Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.

Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S J Bone Miner Metab. 2023; 41(2):248-257.

PMID: 36853423 DOI: 10.1007/s00774-023-01411-4.

References

Naves M, Diaz-Lopez J, Gomez C, Rodriguez-Rebollar A, Rodriguez-Garcia M, Cannata-Andia J . The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int. 2003; 14(6):520-4. DOI: 10.1007/s00198-003-1405-4. View

Lee C, Chen C, Lu S, Tung H, Chou W, Wang J . Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol. 2003; 38(1):95-101. DOI: 10.1080/00365520310000500. View

Briesacher B, Andrade S, Yood R, Kahler K . Consequences of poor compliance with bisphosphonates. Bone. 2007; 41(5):882-7. DOI: 10.1016/j.bone.2007.07.009. View

Haynes R, Sackett D, Taylor D . How to detect and manage low patient compliance in chronic illness. Geriatrics. 1980; 35(1):91-3, 96-7. View

Hawkes W, Wehren L, Orwig D, Hebel J, Magaziner J . Gender differences in functioning after hip fracture. J Gerontol A Biol Sci Med Sci. 2006; 61(5):495-9. DOI: 10.1093/gerona/61.5.495. View

Lau E, Ong K, Kurtz S, Schmier J, Edidin A . Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2008; 90(7):1479-86. DOI: 10.2106/JBJS.G.00675. View

Hasserius R, Karlsson M, NILSSON B, Redlund-Johnell I, Johnell O . Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int. 2003; 14(1):61-8. DOI: 10.1007/s00198-002-1316-9. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Chen C, Lin C, Kao C . Relation Between Hepatitis C Virus Exposure and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine (Baltimore). 2015; 94(47):e2086. PMC: 5058989. DOI: 10.1097/MD.0000000000002086. View

10.

Puisto V, Rissanen H, Heliovaara M, Impivaara O, Jalanko T, Kroger H . Vertebral fracture and cause-specific mortality: a prospective population study of 3,210 men and 3,730 women with 30 years of follow-up. Eur Spine J. 2011; 20(12):2181-6. PMC: 3229726. DOI: 10.1007/s00586-011-1852-0. View

11.

GORDIS L . Symposium in honor of Abraham M. Lilienfeld. Chronic disease epidemiology at the threshold of a new decade. Am J Epidemiol. 1980; 112(2):169-77. DOI: 10.1093/oxfordjournals.aje.a112981. View

12.

Bedimo R, Maalouf N, Lo Re 3rd V . Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS. 2016; 11(3):285-93. PMC: 6161492. DOI: 10.1097/COH.0000000000000259. View

13.

Shiraki M, Kuroda T, Tanaka S . Established osteoporosis associated with high mortality after adjustment for age and co-mobidities in postmenopausal Japanese women. Intern Med. 2011; 50(5):397-404. DOI: 10.2169/internalmedicine.50.4437. View

14.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

15.

Halpern R, Becker L, Iqbal S, Kazis L, Macarios D, Badamgarav E . The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011; 17(1):25-39. PMC: 10437983. DOI: 10.18553/jmcp.2011.17.1.25. View

16.

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D . Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44-7. DOI: 10.1111/j.1524-4733.2007.00213.x. View

17.

Huybrechts K, Ishak K, Caro J . Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2005; 38(6):922-8. DOI: 10.1016/j.bone.2005.10.022. View

18.

Kripalani S, Yao X, Haynes R . Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007; 167(6):540-50. DOI: 10.1001/archinte.167.6.540. View

19.

Center J, Bliuc D, Nguyen N, Nguyen T, Eisman J . Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96(4):1006-14. DOI: 10.1210/jc.2010-2730. View

20.

Tuominen O, Ylitalo-Heikkala R, Vehmas T, Mucha I, Ylitalo P, Riutta A . Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol. 2006; 28(6):361-7. DOI: 10.1358/mf.2006.28.6.1003551. View